Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 406

1.

Gender differences in HIV disease progression and treatment outcomes among HIV patients one year after starting antiretroviral treatment (ART) in Dar es Salaam, Tanzania.

Mosha F, Muchunguzi V, Matee M, Sangeda RZ, Vercauteren J, Nsubuga P, Lyamuya E, Vandamme AM.

BMC Public Health. 2013 Jan 15;13:38. doi: 10.1186/1471-2458-13-38.

2.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
3.

Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.

Cornell M, Schomaker M, Garone DB, Giddy J, Hoffmann CJ, Lessells R, Maskew M, Prozesky H, Wood R, Johnson LF, Egger M, Boulle A, Myer L; International Epidemiologic Databases to Evaluate AIDS Southern Africa Collaboration.

PLoS Med. 2012;9(9):e1001304. Epub 2012 Sep 4.

4.
5.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

6.
7.

Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.

Paredes R, Mocroft A, Kirk O, Lazzarin A, Barton SE, van Lunzen J, Katzenstein TL, Antunes F, Lundgren JD, Clotet B.

Arch Intern Med. 2000 Apr 24;160(8):1123-32.

PMID:
10789605
8.

Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.

Dou Z, Xu J, Jiao JH, Ma Y, Durako S, Yu L, Zhao Y, Zhang F.

PLoS One. 2011;6(8):e22707. doi: 10.1371/journal.pone.0022707. Epub 2011 Aug 16.

9.

Prognostic value of virological and immunological responses after 6 months of antiretroviral treatment in adults with HIV-1 infection in sub-Saharan Africa.

De Luca A, Marazzi MC, Mancinelli S, Ceffa S, Altan AM, Buonomo E, Prosperi MC, Pedruzzi B, Noorjehan AM, Scarcella P, Liotta G, Palombi L.

J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):236-44. doi: 10.1097/QAI.0b013e31824276e9.

PMID:
22327246
10.

Initial plasma HIV-1 RNA levels and progression to AIDS in women and men.

Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC.

N Engl J Med. 2001 Mar 8;344(10):720-5.

11.

Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.

Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, Downing R, Coutinho A, Solberg P, Alexander LN, Tappero J, Campbell J, Moore DM.

BMJ. 2011 Nov 9;343:d6792. doi: 10.1136/bmj.d6792.

12.

Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania.

Mosha F, Ledwaba J, Ndugulile F, Ng'ang'a Z, Nsubuga P, Morris L, Kasubi M, Swai A, Vercauteren J, Vandamme AM.

J Infect Dev Ctries. 2014 Jul 14;8(7):845-52. doi: 10.3855/jidc.3879.

13.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
14.
15.

Prevalence of hepatitis B co-infection and response to antiretroviral therapy among HIV-infected patients in Tanzania.

Hawkins C, Christian B, Ye J, Nagu T, Aris E, Chalamilla G, Spiegelman D, Mugusi F, Mehta S, Fawzi W.

AIDS. 2013 Mar 27;27(6):919-27. doi: 10.1097/QAD.0b013e32835cb9c8.

PMID:
23196935
16.

Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study.

Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T, Walsh J, Fisher M, Johnson M, Post F, Easterbrook P, Gazzard B, Palfreeman A, Orkin C, Leen C, Gompels M, Dunn D, Delpech V, Pillay D, Sabin CA; UK CHIC Study Steering Committee.

Antivir Ther. 2011;16(6):805-14. doi: 10.3851/IMP1818.

PMID:
21900712
17.

Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.

Thorsteinsson K, Ladelund S, Jensen-Fangel S, Johansen IS, Katzenstein TL, Pedersen G, Storgaard M, Obel N, Lebech AM.

BMC Infect Dis. 2012 Nov 12;12:293. doi: 10.1186/1471-2334-12-293.

18.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
19.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
20.

Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.

Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E.

Clin Infect Dis. 2012 Mar;54(6):853-61. doi: 10.1093/cid/cir900. Epub 2011 Dec 12.

Items per page

Supplemental Content

Write to the Help Desk